Estimating standard performance measures of opportunistic screening for prostate cancer;Stima di misure di processo standard dell'attività spontanea di screening per il cancro prostatico

Epidemiologia e Prevenzione

Volumn 32, Issue 6, 2008, Pages 285-293

  Leoni, Maurizio ^a   Falcini, Fabio ^b   Ravaioli, Alessandra ^b   Foca, Flavia ^b   Andalò, Gianni ^c   Benini, Franca ^a   Dal Pozzo, Claudio ^a   Ricci, Rosalba ^d   Naldoni, Carlo ^e   Bucchi, Lauro ^b  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c OSPEDALE DEGLI INFERMI   (Italy)

^d AUSL   (Italy)

^e CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Mass screening; Prostate cancer; Prostate specific anrigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; EARLY DIAGNOSIS; GENETIC SCREENING; HUMAN; IMMUNOLOGY; ITALY; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; RISK;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; ITALY; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958161407     PISSN: 11209763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003;361(9363):1122-28.
2. De Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97(2):237-44.
3. Roemeling S, Schroder FH. Prostate cancer: risks and benefìts of screening. Nat Clin Pract Urol 2006;3(1):4-5.
4. Bunting PS, Chong N, Holowaty EJ, Goel V. Prostate-specifìc antigen utilization in Ontario: extent of testing in patients with and without cancer. Clin Biochem 1998;31(6):501-11.
5. Ito K, Yamamoto T, Kubota Y et al. Usefulness of age-specific reference range of prostate-specifìc antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 2000;56(2):278-82.
6. Paez A, Lujan M, Uanes L et al. PSA-use in a Spanish industriai area. Eur Urol 2002;41(2):162-66.
7. Li X, Tsuji I, Kuwahara M et al. Mass screening of prostate cancer in Changchun City of China. Int Urol Nephrol 2004;36(4):541-48.
8. McLernon DJ, Donnan PT, Gray M, Weller D, Sullivan F. Receiver operating characteristics of the prostate specific antigen test in an unselected population. J Med Screen 2006;13(2):102-07.
9. Chamberlain J. Reasons that some screening programmes fail to control cervical cancer. In: Hakama M, Miller AB, Day NE (eds). Screening for cancer of the uterine cervix. Lyon, International Agency for Reasearch on Cancer, 1996, 161-64.
10. Quaglia A, Parodi S, Grosclaude P, Martinez-Garcia C, Coebergh JW, Vercelli M. Differences in the epidemie rise and decrease of prostate cancer among geographical areas in Southern Europe: an analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer 2003;39(5):654-65.
11. Zanetti R, Crosignani P, Rosso S. Cancer in Italy: incidence data front cancer registries, second volume, 1988-1992. Roma, Il Pensiero Scientifico Editore, 1997.
12. Ronco G, Giubilato P, Naldoni C et al. Livello di attivazione e indicatori di processo dei programmi organizzati di screening dei tumori del collo dell'utero in Italia. In: Rosselli Del Turco M, Zappa M (eds). Osservatorio Nazionale Screening: sesto rapporto. Milano, Edizioni Inferenze, 2007, 52-68.
13. Otto SJ, Van Der Cruijsen IW, Liem MK et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105(3):394-99.
14. Zappa M, Ciatto S. Cervix cancer: case-control studies on screening. In: Sankila R, Démaret E, Hakama M, Lynge E, Schouten LJ, Parkin DM (eds). Evaluation and monitoring of screening programmes. Lyon, International Agency for Research on Cancer, 2000, 99-118.
15. Bucchi L, Pierri C, Caprara L, Cortecchia S, De Lillo M, Bondi A. Computerized monitoring for integrated cervical screening: rationale, methods and indicators of participation. Patbologica 2003;95(1):9-21.
16. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Pam Pract 2002;3:19.
17. D'Ambrosio G, Samani F, Cancian M, De Mola C. Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 2004;13(5):383-86.
18. Fowler FJ Jr, Bin L, Collins MM et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am JMed 1998;104(6):526-32.
19. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U. S. Preventive Services Task Force. Ann Intem Med 2002;137(11):917-29.
20. Wasson JH, Bubolz TA, Yao GL, Barry MJ. Prostate biopsies in men with limited life expectancy. Eff Clin Pract 2002;5(3):137-42.
21. Van Der Cruijsen-Koeter IW, Wildhagen MF, De Koning HJ, Schroder FH. The value of current diagnostic tests in prostate cancer screening. BJUInt 2001;88(5):458-66.
22. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseise. JAMA 1992;267(16):2215-20.
23. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med 1995;333(21):1401-05.
24. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100(7):1397-405.
25. Postma R, Schròder FH, Van Leenders GJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - section Rotterdam: a comparison of two rounds of screening. Eur Uni 2007;52(1):89-97.
26. Van Der Kwast TH, Ciatto S, Martikainen PM et al. Detection rates of high-grade prostate cancer during subsequent screening visits: results of the European Randomized Screening Study for Prostate Cancer. Int J Cancer 2006;118(10):2538-42.